宋本艳,胡 强,任世友,舒立群,王利玲.舒血宁注射液联合布地耐德对COPD急性加重期患者血清MMP-9,IL-6,IL-8,TNF-α及肺功能的影响[J].现代生物医学进展英文版,2017,17(21):4163-4167. |
舒血宁注射液联合布地耐德对COPD急性加重期患者血清MMP-9,IL-6,IL-8,TNF-α及肺功能的影响 |
Influence of Shuxuening Injection Combined with Budesonide on Serum Levels of MMP-9, IL-6, IL-8 and TNF-α and Lung Function of COPD Patients with Acute Aggravating Period |
Received:January 13, 2017 Revised:February 10, 2017 |
DOI:10.13241/j.cnki.pmb.2017.21.041 |
中文关键词: 慢性阻塞性肺病急性加重期 舒血宁注射液 布地奈德 细胞因子 肺功能 |
英文关键词: Chronic obstructive pulmonary disease with acute aggravating period Shuxuening injection Budesonide Cytokines Lung function |
基金项目:四川省自然科学基金项目(8BF3524) |
|
Hits: 272 |
Download times: 146 |
中文摘要: |
摘要 目的:探讨舒血宁注射液联合布地耐德对慢性阻塞性肺病(COPD)急性加重期患者血清基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)及肺功能的影响。方法:将112例COPD急性加重期患者参照随机数表法分作对照组与观察组,每组各56例。对照组采用布地奈德治疗,观察组基于对照组加以舒血宁注射液治疗。比较两组总有效率,治疗前后血清MMP-9、IL-6、IL-8、TNF-α、丙二醛(MDA)、超氧化物歧化醇(SOD)水平、二氧化碳分压(PaCO2)、血氧分压(PaO2),气峰流速(PEF)、最大呼气中期流速(MMEF)、用力肺活量(FVC)、CD3+、CD4+、CD8+、CD4+/CD8+及不良反应的发生情况。结果:观察组总有效率显著高于对照组94.64% vs 80.35 %(P<0.05)。观察组治疗后血清MMP-9、IL-6、IL-8、TNF-α、MDA水平、PaCO2、CD8+均明显低于对照组(P<0.05),血清SOD水平、PaO2、PEF、MMEF、FVC、CD3+、CD4+、CD4+/CD8+均明显高于对照组(P<0.05)。两组不良反应的发生情况比较差异无统计学意义(P>0.05)。结论:舒血宁注射液联合布地奈德治疗COPD急性加重期患者的疗效确切,可降低血清MMP-9、IL-6、IL-8、TNF-α水平,改善肺功能,减轻氧化应激并改善动脉血气及免疫功能。 |
英文摘要: |
ABSTRACT Objective: To investigate the influence of shuxuening injection combined with budesonide on the serum levels of matrix metalloproteinases-9 (MMP-9) and interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α(TNF-α) and lung function of chronic obstructive pulmonary disease (COPD) patients with acute aggravating period. Methods: 112 cases of COPD patients with acute aggravating period were divided into the control group and the observation group with 56 cases in each group. The control group was treated by budesonide, while the observation group was treated based on the control group combined with Shuxuening injection. The total effective rate, serum levels of MMP-9, IL-6, IL-8, TNF-α, propylene glycol (MDA), superoxide disproportionation alcohol (SOD), CO2 partial pressure (PaCO2), blood oxygen partial pressure (PaO2), peak velocity of flow (PEF), maximum mid expiratory gas flow velocity (MMEF), forced vital capacity (FVC), CD3+, CD4+, CD8+, CD4+/CD8+, and the occurrence of adverse reactions before and after the treatment were compared between two groups. Results: The total effective rate of observation group was higher than that of the control group (94.64% vs 80.35 %, P<0.05). After the treatment, the serum levels of MMP-9, IL-6, IL-8, TNF-α, MDA, PaCO2, CD8+ of observation group were lower than those of the control group (P<0.05). The serum levelof SOD, PaO2, PEF, MMEF, FVC, CD3+, CD4+, CD4+/CD8+ of observation group were higher than those of the control group (P<0.05). The occurrence of adverse reactions showed no difference between the two groups(P>0.05). Conclusion: Shuxuening injection combined with budesonide was effective in the treatment of COPD patients with acute aggravating period, which could decrease the serum levels of MMP-9, IL-6, IL-8 and TNF-α, improve the lung function, reduce the oxidative stress and improve the arterial blood gas and immune function. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|